Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing.
BACKGROUND
Sarcopenia is a major contributor to frailty and mortality in ageing and obesity and is tightly linked to metabolic dysfunction. Imeglimin is a first-in-class oral hypoglycaemic agent targeting mitochondrial function; however, despite the central role of mitochondria in skeletal muscle...
